Mirari Biosciences Granted U.S. Patent for Microwave DNA Technology

Share Article

Mirari Biosciences, Inc. has received U.S. Patent 8,431,414, for inventing a method of vastly accelerating nucleic acid testing using low power microwaves.

Mirari Biosciences, a pioneer in the field of microwave biochemistry, announces the award of a U.S. Patent broadly covering the use Company's microwave technology to shorten the time required for nucleic acid analysis, including DNA testing and polymerase chain reaction (PCR) amplification.

U.S. Patent 8,431,414 recognizes of the invention of Mirari’s Microwave-Accelerated Surface Chemistry™ (MASC™) technology in the acceleration of nucleic acid testing. Shorter testing times are needed in many biomedical applications including:

  •     Screening of genes and mutations in humans, animals, and plants.
  •     PCR amplification of genes.
  •     DNA and RNA microarray and bead-based detection of genetic activity.

Microwave-accelerated nucleic acid technology has immense potential in many commercial areas including clinical diagnostics, human therapeutics, point–of–care and home consumer testing, forensics, biodefense testing, agricultural and food safety testing, drug development, and veterinary medicine. Because extremely low-power microwaves are used, future rapid nucleic acid testing devices can be miniaturized, even pocket-sized.

“This valuable patent supports Mirari’s mission, which is to save lives and money by shrinking biomedical testing times,” said Dr. Mark Martin, President/CEO of Mirari.

Mirari has aggressively patented cutting edge technologies in the United States and around the world. The Company’s dominant and growing patent portfolio illustrates Mirari’s leadership in Microwave-Accelerated Biochemistry. In addition to ongoing internal development, Mirari seeks to partner or license its technologies to help bring important products to market.

About Mirari Biosciences, Inc.

Founded in 2000, Mirari is a developing platform biotechnology dedicated to streamlining Life Sciences R&D, Clinical Diagnostics, and other areas through the invention of valuable new molecular detection technologies. Mirari's MASC™, Microwave Fluidics, and Peplica™ technologies embody this mission.

Media Contact:

Mark T. Martin, Ph.D.
240-447-6456
http://www.miraribiosciences.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mark T. Martin, Ph.D.
Visit website